These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1514 related items for PubMed ID: 793446

  • 1. The influence of pharmaceutical compounds on male fertility.
    Neumann F, Diallo FA, Hasan SH, Schenck B, Traore I.
    Andrologia; 1976; 8(3):203-35. PubMed ID: 793446
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens.
    Guerin JF, Rollet J.
    Int J Androl; 1988 Jun; 11(3):187-99. PubMed ID: 2970439
    [Abstract] [Full Text] [Related]

  • 3. Medium dose cyproterone acetate (CPA): effects on hormone secretion and on spermatogenesis in men.
    Moltz L, Römmler A, Post K, Schwartz U, Hammerstein J.
    Contraception; 1980 Apr; 21(4):393-413. PubMed ID: 6771095
    [Abstract] [Full Text] [Related]

  • 4. Endogenous antispermatogenic agents: prospects for male contraception.
    Ewing LL, Robaire B.
    Annu Rev Pharmacol Toxicol; 1978 Apr; 18():167-87. PubMed ID: 206192
    [Abstract] [Full Text] [Related]

  • 5. Target sites for suppressing fertility in the male.
    Prasad MR, Rajalakshmi M.
    Adv Sex Horm Res; 1976 Apr; 2():263-87. PubMed ID: 797248
    [Abstract] [Full Text] [Related]

  • 6. Developments in the control of testicular function.
    Swerdloff RS, Wang C, Bhasin S.
    Baillieres Clin Endocrinol Metab; 1992 Apr; 6(2):451-83. PubMed ID: 1377467
    [Abstract] [Full Text] [Related]

  • 7. Development of male-fertility-regulating agents.
    Ray S, Verma P, Kumar A.
    Med Res Rev; 1991 Sep; 11(5):437-72. PubMed ID: 1943328
    [Abstract] [Full Text] [Related]

  • 8. Endocrine approaches to male fertility control.
    Knuth UA, Nieschlag E.
    Baillieres Clin Endocrinol Metab; 1987 Feb; 1(1):113-31. PubMed ID: 3297020
    [Abstract] [Full Text] [Related]

  • 9. Reversible inhibition of sperm production and gonadotrophin secretion in men following combined oral medroxyprogesterone acetate and percutaneous testosterone treatment.
    Soufir JC, Jouannet P, Marson J, Soumah A.
    Acta Endocrinol (Copenh); 1983 Apr; 102(4):625-32. PubMed ID: 6221496
    [Abstract] [Full Text] [Related]

  • 10. Use of low-dosage oral cyproterone acetate as a male contraceptive.
    Wang C, Yeung KK.
    Contraception; 1980 Mar; 21(3):245-72. PubMed ID: 6771091
    [Abstract] [Full Text] [Related]

  • 11. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
    Behre HM, Nashan D, Hubert W, Nieschlag E.
    J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
    [Abstract] [Full Text] [Related]

  • 12. The regulation of male fertility: the state of the art and future possibilities.
    de Krester DM.
    Contraception; 1974 Jun; 9(6):561-600. PubMed ID: 4614937
    [Abstract] [Full Text] [Related]

  • 13. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
    Wallace EM, Gow SM, Wu FC.
    J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955
    [Abstract] [Full Text] [Related]

  • 14. In vitro steroid metabolic studies in human testes I: Effects of estrogen on progesterone metabolism.
    Rodriguez-Rigau LJ, Tcholakian RK, Smith KD, Steinberger E.
    Steroids; 1977 Jun; 29(6):771-86. PubMed ID: 910250
    [Abstract] [Full Text] [Related]

  • 15. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ, Conway AJ, Howe CJ, Turner L, Mackey MA.
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
    [Abstract] [Full Text] [Related]

  • 16. Comparative studies of the ethynyl estrogens used in oral contraceptives. III. Effect on plasma gonadotropins.
    Goldzieher JW, de la Peña A, Chenault CB, Cervantes A.
    Am J Obstet Gynecol; 1975 Jul 01; 122(5):625-36. PubMed ID: 1146928
    [Abstract] [Full Text] [Related]

  • 17. Low dose of cyproterone acetate and testosterone enanthate for contraception in men.
    Meriggiola MC, Bremner WJ, Costantino A, Di Cintio G, Flamigni C.
    Hum Reprod; 1998 May 01; 13(5):1225-9. PubMed ID: 9647551
    [Abstract] [Full Text] [Related]

  • 18. Preclinical evaluation of norgestimate, a progestin with minimal androgenic activity.
    Phillips A, Hahn DW, McGuire JL.
    Am J Obstet Gynecol; 1992 Oct 01; 167(4 Pt 2):1191-6. PubMed ID: 1415445
    [Abstract] [Full Text] [Related]

  • 19. Male contraception: current status and future prospects.
    Wu FC.
    Clin Endocrinol (Oxf); 1988 Oct 01; 29(4):443-65. PubMed ID: 3075164
    [Abstract] [Full Text] [Related]

  • 20. Hormones and hormonal target cells in the testis.
    Hansson V, Djoseland O, Torgersen O, Ritzen EM, French FS, Nayfeh SN.
    Andrologia; 1976 Oct 01; 8(3):195-202. PubMed ID: 187086
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 76.